Patents Assigned to Delta Pharmaceuticals, Inc.
-
Patent number: 6300332Abstract: A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound.Type: GrantFiled: July 12, 1999Date of Patent: October 9, 2001Assignee: Delta Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang, Robert W. McNutt, Jr., Hugh O. Pettit, Michael J. Bishop
-
Patent number: 5854249Abstract: A method for the treatment or prophylaxis of one or more conditions or disorders selected from the group consisting of physiological pain, diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depressioysema, apnea, cognitive disorders and gastrointestinal disorders, comprising administration to a subject in need of such treatment or prophylaxis, of a diarylmethylpiperazine or piperidine opioid compound.Type: GrantFiled: May 28, 1997Date of Patent: December 29, 1998Assignee: Delta Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang, Grady Evan Boswell, Dulce Garrido Bubacz, Mark Allan Collins, Ann Otstot Davis, Robert Walton McNutt, Jr.
-
Patent number: 5807858Abstract: The present invention relates to, inter alia, methods and compositions for reducing, treating or preventing respiratory depression in an animal, using a compound of the formula: ##STR1## wherein: Ar, G, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in specification,or a pharmaceutically acceptable ester or salt thereof.Type: GrantFiled: June 5, 1996Date of Patent: September 15, 1998Assignee: Delta Pharmaceutical, Inc.Inventors: Kwen-Jen Chang, Robert W. McNutt, Jr., Hugh O. Pettit, Michael J. Bishop
-
Patent number: 5681830Abstract: Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.Type: GrantFiled: August 3, 1994Date of Patent: October 28, 1997Assignee: Delta Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang, Dulce G. Bubacz, Ann O. Davis, Robert W. McNutt, Jr., Mark A. Collins, Michael J. Bishop
-
Patent number: 5658908Abstract: Diarylmethylpiperazine compounds having utility as receptor-binding species, e.g., for mediating analgesia, and for combatting drug addiction, alcohol addiction, and drug overdose. The compounds may be administered orally, rectally, topically, nasally, ophthalmically, or parenterally (subcutaneously, intramuscularly, and intravenously), for veterinary and human use, and include delta receptor and mu receptor binding species.Type: GrantFiled: August 3, 1994Date of Patent: August 19, 1997Assignee: Delta Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang, Grady Evan Boswell, Dulce Garrido Bubacz, Mark Allan Collins, Ann Otstot Davis, Robert Walton McNutt, Jr.
-
Patent number: 5574159Abstract: Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.Type: GrantFiled: April 28, 1995Date of Patent: November 12, 1996Assignee: Delta Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang, Dulce G. Bubacz, Ann O. Davis, Robert W. McNutt, Jr., Michael J. Bishop
-
Patent number: 5552404Abstract: Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.Type: GrantFiled: April 28, 1995Date of Patent: September 3, 1996Assignee: Delta Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang, Dulce G. Bubacz, Ann O. Davis, Robert W. McNutt, Jr., Michael J. Bishop